Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

999
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
999
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.2K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

956
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
956
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.6K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.6K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.3K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Rheumatology in the Middle East: MRC 2025 Abstracts.

Saudi medical journal·2026
Same author

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

SLC52A3-related Brown-Vialetto-Van Laere syndrome: a large cohort from the Arabian Peninsula.

European journal of human genetics : EJHG·2026
Same author

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Journal of neurology·2026
Same author

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

CNS drugs·2026
Same author

Prevalence and clinical implications of abnormal autoantibodies in Omani patients with multiple sclerosis: A retrospective cross-sectional study.

Multiple sclerosis and related disorders·2026

Related Experiment Video

Updated: Feb 5, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K

Rituximab Treatment in

Roshan Koul1, Amna Al-Futaisi1, Rana Abdelrahim1

  • 1Department of Child Health, Sultan Qaboos University Hospital, Muscat, Oman.

Sultan Qaboos University Medical Journal
|September 14, 2018
PubMed
Summary
This summary is machine-generated.

Myasthenia gravis (MG) in children is rare. Rituximab offered significant improvement or complete remission in two pediatric MG cases resistant to standard treatments.

Keywords:
Case ReportChildrenCholinergic ReceptorsMyasthenia GravisOmanRituximab

More Related Videos

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.7K
Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases
04:25

Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases

Published on: November 8, 2024

2.3K

Related Experiment Videos

Last Updated: Feb 5, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.5K
MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.7K
Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases
04:25

Author Spotlight: Dermatopathology and the Treatment of Sexually Transmitted Diseases

Published on: November 8, 2024

2.3K

Area of Science:

  • Neurology
  • Immunology
  • Pediatrics

Background:

  • Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, causing skeletal muscle weakness.
  • Current treatments like acetylcholinesterase inhibitors and immune-modulators require lifelong administration and can cause side effects.
  • Pediatric MG is uncommon, presenting unique treatment challenges.

Observation:

  • Two pediatric patients with refractory MG were treated at Sultan Qaboos University Hospital.
  • Standard treatments failed to yield significant improvement in these cases.
  • Rituximab was administered as an alternative therapy after conventional treatments were ineffective.

Findings:

  • One patient achieved complete remission following rituximab treatment.
  • The second patient experienced significant clinical improvement with rituximab.
  • Rituximab demonstrated efficacy in severe pediatric MG cases unresponsive to standard care.

Implications:

  • Rituximab may represent a viable therapeutic option for pediatric myasthenia gravis.
  • This suggests potential for improved quality of life in children with refractory MG.
  • Further research into rituximab's long-term effects in pediatric MG is warranted.